Experimental group:pirfenidone

2 trials

Sponsors

State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of DaLian Medical University

Conditions

Fibrosis after Severe Coronavirus Disease 2019 (COVID-19) Pneumoniarheumatoid arthritis

Early Phase 1

Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical study

RecruitingChiCTR2000030892

State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical UniversityFibrosis after Severe Coronavirus Disease 2019 (COVID-19) Pneumonia

Start: 2020-03-06Updated: 2020-03-16

Phase 4

Study on the mechanism of pirfenidone in the treatment of connective tissue disease with interstitial lung disease

Active, not recruitingChiCTR2100046283

The First Affiliated Hospital of DaLian Medical Universityrheumatoid arthritis

Start: 2021-05-30Updated: 2021-12-21